|
- UNII - 31YO63LBSN - Food and Drug Administration
946414-94-4 BMS-936558 BMS-986213 COMPONENT NIVOLUMAB BMS-986298 MDX-1106 MDX1106 NIVOLUMAB [JAN] NIVOLUMAB [MI] NIVOLUMAB [PURPLE BOOK CDER] NIVOLUMAB [USAN] NIVOLUMAB [VANDF]
- NDC 0003-6120 Opdivo Qvantig Injection, Solution Subcutaneous
NIVOLUMAB 120 mg mL - A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells
- OPDIVO U. S. Prescribing Information - BMS
See full prescribing information for OPDIVO OPDIVO® (nivolumab) injection, for intravenous use Initial U S Approval: 2014 ----------------------------RECENT MAJOR CHANGES-------------------------- Indications and Usage (1) 5 2025 Dosage and Administration (2) 5 2025 -----------------------------INDICATIONS AND USAGE--------------------------
- NIVOLUMAB - gsrs. ncats. nih. gov
Record Protection Status Public record Record Status Validated (UNII) Record Version 77 This is an older version of this substance - Ver 77
- OPDIVO (nivolumab) injection Label - Food and Drug Administration
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of
- Nivolumab - Wikipedia
Nivolumab Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication in the class of immune checkpoint inhibitors It selectively binds and blocks the programmed death-1 (PD-1) receptor on T cells, thereby facilitating their activation
- Nivolumab: Uses, Dosage, Side Effects Warnings - Drugs. com
Nivolumab may be used alone or in combination with other medicines, such as ipilimumab (Yervoy) or chemotherapy Nivolumab is an immune checkpoint inhibitor that works by interfering with the growth and spread of cancer cells
- Nivolumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Nivolumab is a PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma
|
|
|